Some five years into a pneumococcal vaccine patent dispute in South Korea, SK Bioscience has emerged victorious over Pfizer.

The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 ...

The deal comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital Markets ...

Pfizer (NYSE:PFE) is overhauling its cardiometabolic ... antagonist and pursuing external opportunities that could include partnerships or acquisitions. That strategic pivot comes as shares ...

Revolve Wealth Partners LLC lifted its holdings ... analysts have recently commented on the stock. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a report on Monday ...

Pharmaceutical and biotechnology company Pfizer marks 70 years of dedication to its mission of advancing patient health in ...

Under the multi-year collaboration agreement, Guardant and Pfizer ... for its global clinical trials, which include China cohorts. In July 2022, Guardant announced a strategic partnership with ...

Pfizer PFE announced that it is in-licensing global development and commercialization rights, ex-China, to SSGJ-707, a ...